Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.465 -0.035 (-2.33%)

Delayed Quote Updated: 10:45 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 13, 2024

ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 13, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 06, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Recap: Allogene Therapeutics Q4 Earnings ↗

March 14, 2024

Via Benzinga

Allogene Therapeutics Earnings Preview ↗

March 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 06, 2024

Via Benzinga

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

April 26, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation ↗

April 18, 2024

Via Benzinga

Topics ETFs

3 Meme Stocks to Sell and Replace With Meme Coins ↗

April 11, 2024

For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs.

Via InvestorPlace

Allogene Therapeutics Announces Q2 Investor Conference Participation

April 09, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗

March 14, 2024

ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

March 14, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

March 12, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

March 05, 2024

Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

February 28, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

February 16, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Via Benzinga

Topics Stocks

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

January 16, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst ↗

January 05, 2024

Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal...

Via Benzinga

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 05, 2024

Shares of Applied Therapeutics, Inc.

Via Benzinga

Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts ↗

January 05, 2024

Today, investors in Allogene and ALLO stock aren't cheering a cash burn reduction strategy, with the stock sinking over 15% on the news.

Via InvestorPlace

Topics Workforce

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 05, 2024

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

Via InvestorPlace

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 05, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 04, 2024

Via Benzinga

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 04, 2024

From Allogene Therapeutics, Inc.; Foresight Diagnostics

Via GlobeNewswire

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 04, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 02, 2024

Shares of Longboard Pharmaceuticals, Inc.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.